Loading…
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | $-80M | $-69M | $-77M | -33.5% | - | - |
| 2024 | - | - | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2024 | 2025 |
|---|---|---|
| Total Revenue | - | 13 |
| Operating Revenue | - | 13 |
| Operating Expense | - | 94.07 |
| Research And Development | - | 74.04 |
| Selling General And Administration | - | 20.03 |
| Total Expenses | - | 94.07 |
| Operating Income | - | -81.07 |
| Total Operating Income As Reported | - | -81.07 |
| EBITDA | - | -79.68 |
| Normalized EBITDA | - | -88.61 |
| EBIT | - | -81.07 |
| Interest Income | - | 3.32 |
| Net Interest Income | - | 3.32 |
| Other Non Operating Income Expenses | - | -0.05 |
| Other Income Expense | - | 8.88 |
| Interest Income Non Operating | - | 3.32 |
| Net Non Operating Interest Income Expense | - | 3.32 |
| Pretax Income | - | -68.87 |
| Tax Rate For Calcs | - | 0 |
| Tax Effect Of Unusual Items | - | 0 |
| Net Income Continuous Operations | - | -68.87 |
| Net Income From Continuing And Discontinued Operation | - | -68.87 |
| Net Income From Continuing Operation Net Minority Interest | - | -68.87 |
| Net Income | - | -68.87 |
| Net Income Common Stockholders | - | -68.87 |
| Net Income Including Noncontrolling Interests | - | -68.87 |
| Normalized Income | - | -77.80 |
| Diluted NI Availto Com Stockholders | - | -68.87 |
| Basic Average Shares | 16 | - |
| Diluted Average Shares | 16 | - |
| Reconciled Depreciation | - | 1.39 |
| Total Unusual Items | - | 8.93 |
| Total Unusual Items Excluding Goodwill | - | 8.93 |
| Gain On Sale Of Security | - | 8.93 |
| General And Administrative Expense | - | 20.03 |
| Other Gand A | - | 7.48 |
| Salaries And Wages | - | 12.54 |
| Otherunder Preferred Stock Dividend | - | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| EVMNthis co. | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% |
| -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Peer Median | - | -9.39 | 3.70 | -32.0% | -7.97 | |